In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Kadmon Holdings (KDMN), with a price target of $25. The company’s shares closed yesterday at $2.85.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.5% and a 48.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
Kadmon Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $14.50, a 408.8% upside from current levels. In a report issued on February 26, Citigroup also upgraded the stock to Buy with a $4 price target.
See today’s analyst top recommended stocks >>
Based on Kadmon Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $41.52 million. In comparison, last year the company had a GAAP net loss of $18.19 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics. Its products include Ribasphere RibaPak, Tetrabenazine, Valganciclovir, Abacavir, Entecavir, Lamivudine, and Zidovudine.